Floatz logo

dm002

Colorectal Neoplasms

Xadcera Biopharmaceutical (Suzhou) Co., Ltd.Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
73/ 100

Competitive context

117 Active assets in the Colorectal Neoplasms cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Rutgers, The State University of New Jersey
Phase 4BBB
Capecitabine
Rutgers, The State University of New Jersey
Phase 4BBB
Eloxatin
Peking University Cancer Hospital & Institute
Phase 4BBB
Irinotecan
Shanghai Zhongshan Hospital
Phase 4BBB
Ferric Carboxymaltose [Ferinject]
Nottingham University Hospitals NHS Trust
Phase 4BBB

View all 50 →

Same molecule, other indications

dm002 is also rated in:

endometrial cancerDormant
CC
Indicative ·
41 / 100
View asset →
carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
ovarian neoplasmDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →